<DOC>
	<DOCNO>NCT00349089</DOCNO>
	<brief_summary>The purpose randomize phase II trial determine clinical feasibility - term patient without dose limit toxicity premature treatment withdrawal death - combination Cisplatin Pemetrexed combination Cisplatin Vinorelbine . The combination Cisplatin / Pemetrexed assume distinctly less toxic Vinorelbine / Cisplatin .</brief_summary>
	<brief_title>Trial Refinement Early Stage Lung Cancer Adjuvant Therapy</brief_title>
	<detailed_description>Derived recent large randomize clinical trial , clear evidence adjuvant chemotherapy stage IB-IIB ( incidental IIIA ) non-small cell lung cancer ( Arriagada et al. , 2004 ; Winton et al. , 2005 , Strauss et al. , 2004 , Douillard et al. , 2005 ) . The majority patient adjuvant treatment set receive combination Cisplatin Vinorelbine ( Aragiada et al. , 2004 ; Winton et al. , 2005 ; Douillard et al. , 2005 ) . This combination improve 5 year-survival rate 15 % ( 54 % 69 % ) ( Winton et al. , 2005 ) . However , combination Cisplatin Vinorelbine result rate grade 3/4 neutropenia around 75 % , rate febrile neutropenia 12.5 % rate treatment relate death 1-2 % . Up 77 % patient least one dose reduction omission 55 % required one dose delay , relate neutropenia . Only 50 % patient randomize combination cisplatin vinorelbine receive intend dose Vinorelbine ( dose reduction mainly due toxicity ) 50 % patient complete four cycle chemotherapy ( Winton et al. , 2005 , Douillard et al. , 2005 , Alam et al. , 2005 ) . Therefore seem reasonable test less toxic regimen also early stage R0 resection tumor , reduce toxicity might improve feasibility drug delivery , compliance convenience treatment patient hence perhaps survival . Pemetrexed , folate antimetabolite , show clear activity non-small cell lung cancer several Phase II study Pemetrexed combination Cisplatin , Oxaliplatin , Carboplatin show efficacy similar standard platinum doublet , response rate 27 % 45 % median survival 8.9 10.9 month ( Scagliotti et al. , 2005 ; Clarke et al. , 2002 ; Rusthoven et al. , 1999 ; Manegold et al. , 2000 ; Shepherd et al. , 2001 ) . The combination platin Pemetrexed easily deliver well tolerate . Furthermore , result 25 % rate grade 3/4 neutropenia vitamin supplement patient incidence febrile neutropenia &lt; 1 % . Dose reduction occur 2-4 % patient dose delivery intend Pemetrexed platin dose excellent dose delivery Pemetrexed 95 % ( Hanna et al. , 2004 ; Vogelzang et al. , 2003 , Scagliotti et al. , 2005 ) . In randomized phase II trial , clinical feasibility combination Cisplatin Pemetrexed well combination Cisplatin Vinorelbine assess . Treatment consider clinical feasibility dose limit toxicity observe , non-acceptance patient lead premature withdrawal , death due cancer cancer therapy occur . Patients randomize accord center , lobectomy vs. pneumonectomy N0 vs. N1 4 cycle ( arm A ) 500 mg/m2 pemetrexed d1 , Cisplatin 75 mg/m2 d1 , q d22 versus ( arm B ) 25 mg/m2 Vinorelbine d1 , 8 , 15 , 22 , Cisplatin 50 mg/m2 d1+8 ; q d29 . Radiotherapy maintenance therapy intend . Study drug administration begin d28 d42 R0 resection tumor within 14 day randomization . In initial study phase 36 patient ( i.e . 18 treatment arm ) accrue confirm feasibility . In second step , patient recruit total number 134 ( i.e . 67 case per treatment arm ) . Patients followed-up 3 monthly interval first 2 year start 30 day end last cycle 3rd year patient followed-up 6 monthly interval .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion : Histopathologically confirm diagnosis nonsmall cell lung cancer ( NSCLC ) , pathologic stage IB , IIA , IIB T3N1 ( without need radiotherapy ) . Complete tumor resection without detectable residual tumor include negative margin ( R0 ) systematic intraoperative dissection mediastinal lymph node course lymph node dissection comprise lymph node level remove standard right left side resection . The dissection assure removal mediastinal lymph node 1,5 cm preoperative CT scan . Study drug administration administer patient full recovery surgery begin d28 d42 postoperatively The following histological tumor type eligible : Squamous Cell Carcinoma Adenocarcinoma ( include adenocarcinoma bronchioloalveolar differentiation ) Large Cell Carcinoma ( exclude tumor slight area small cell carcinoma ) Mixed Cell Carcinoma without small cell fraction Provision inform consent accord local regulatory requirement participation study Age ≥ 18 year ; &lt; 75 Years Karnofsky Performance Status 80 % ECOG 1 Adequate hematological laboratory parameter Hemoglobin 10 g/dl ANC 1500/µl Platelets 100000/µl Adequate hepatic laboratory parameter Bilirubin 1.5 x UNL ( UNL=Upper Normal Limit ) ASAT/ALAT 2 x UNL Adequate renal laboratory parameter Creatinine 1,5 mg/dl Calculated Creatinine Clearance 60 ml/min Cardiac function allow cisplatin chemotherapy ( case doubt echocardiography mandatory document LVEF &gt; 49 % ) Electrocardiogram without significant cardiac arrhythmia FEV1 1.2 l postoperatively Respiratory function impede Cisplatinbased chemotherapy assess either absolute DLCO capillary / arterial BGA rest condition ( absolute DLCO &gt; 40 % pO2 &gt; 60 mmHg rest condition ) Agreement patient use effective method contraception Negative pregnancy test woman childbearing potential unless postmenopausal baseline . ( Postmenopausal woman must amenorrheic least 12 month consider non childbearing potential ) Exclusion criterion : Presence Pancoast tumor Involvement N2/N3 lymph node Distant metastases The following histological tumor type exclude Pure bronchioloalveolar carcinoma Mixed cell carcinoma small cell fraction Large Cell Carcinoma area small cell carcinoma Pregnancy lactation period Other coexist malignancy malignancy diagnose within last 5 year exception CIS cervix nonmelanomatous skin cancer . Patients curatively treat free disease least 5 year discuss Principal Investigator ( LKP ) inclusion . Radio and/or chemotherapy within last five year Concurrent administration antitumor therapy Patients compliant vitamin ( folic acid vitamin B12 ) intake administration possible Hypersensitivity Pemetrexed excipients Alimta® Hypersensitivity Cisplatin platinum compound Hypersensitivity Vinorelbin vincaalkaloid Patient previously complete withdrawn study study respective medication study Treatment investigational new drug , currently within last 30 day , and/or participation another clinical trial , currently last 12 week , and/or previous participation study History psychological illness condition interfere patient ability understand requirement study Patients clinically significant disease opinion investigator likely put patient risk interfere evaluation patient 's safety study outcome . This include , limited : Clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 6 month Uncontrolled hypertension Interstitial pneumonia extensive symptomatic interstitial fibrosis lung pleural effusion ascites , cause respiratory compromise . Patients sero ( pneumo ) thorax hemipneumonectomy lobectomy exclude . Those patient must monitor toxicity closely Any active uncontrolled infection Organ allografts Patients neurologic disorder A history presence CNS disorder psychiatric disability judge Investigator clinically significant and/or interfere compliance A serious concomitant systemic disorder ( e.g . active infection include HIV ) opinion investigator would compromise patient ability complete study Postoperative complication surgeryrelated condition could interfere study participation Hearing function / tinnitus impede chemotherapy Cisplatin / Vinorelbine Alcohol and/or drug abuse Patient unable interrupt high dose salicylate ( like aspirin ) nonsteroidal antiinflammatory drug ( NSAID´s ) 5day period start 2 day administration Pemetrexed ( 8day period longacting agent piroxicam ) Patients regularly observed psychological , sociological geographical reason concomitant condition permit adequate followup compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>clinical feasibility rate</keyword>
</DOC>